Lycia Therapeutics Stock Soars 67% on Its Nasdaq Debut: Inside the Upsized $317.5 Million IPO

The Short Answer

Lycia Therapeutics (Nasdaq: LYCA) closed its first day of trading on Friday, October 23, 2026, up about 67% from its $18 IPO price, after opening at $28.55 and trading as high as $36.49 during the session. The South San Francisco biotech had priced an upsized initial public offering of 17.64 million shares at the top of its range the night before, raising about $317.5 million in gross proceeds. By Friday's close, a company priced at a post-money valuation of about $990.6 million was worth nearly $1.7 billion, according to BioCentury.

What Happened

Lycia priced its IPO on Thursday evening, October 22, selling 17,640,000 shares at $18.00 each — the top of its marketed $16 to $18 range. The deal was upsized from the 14.7 million shares in its prospectus, a sign underwriters saw enough demand to sell more stock at the full price. All of the shares were sold by the company, and Lycia also granted underwriters a 30-day option to buy up to 2,646,000 additional shares at the IPO price.

Trading began Friday on the Nasdaq Global Select Market under the symbol LYCA. The stock opened at $28.55, more than 58% above the IPO price, pushed as high as $36.49 — briefly more than double the offering price — and closed up roughly 67% for the day, BioCentury reported. The offering itself is expected to close on October 26, subject to customary conditions.

Jefferies, TD Cowen, Evercore ISI and Guggenheim Securities acted as joint book-running managers, with LifeSci Capital as a passive book-runner.

What Lycia Actually Does

Lycia is a clinical-stage biotechnology company developing therapies designed to degrade disease-causing extracellular proteins — proteins outside cells that drive disease — rather than simply block them. Its initial focus is autoimmune, inflammatory and allergic diseases.

Its lead candidates include LCA-0061, aimed at food allergy and other allergic diseases, and LCA-0321, aimed at Graves' disease. The company's platform is based on the work of Dr. Carolyn Bertozzi, a Nobel laureate on the Stanford faculty, according to its prospectus as summarized by IPOScoop. Lycia said it intends to use the IPO proceeds to fund clinical trials.

Before the IPO, its largest shareholders included Versant Ventures (18.9% pre-IPO, falling to 13.5% after), Venrock Healthcare Capital (12.8%, falling to 9.2%) and Redmile Biopharma (11.1%, falling to 8.0%), with RTW Investments, Janus Henderson and Blue Owl also among the principal holders.

Why It's Blowing Up

Three things collided on Friday. First, the deal itself signaled demand before trading even started: an upsized offering priced at the very top of the range is the clearest pre-market signal an IPO can send. Second, the first-day pop was outsized even by hot-IPO standards — a stock that opens 58% above its offering price and trades at double that price intraday gets attention fast. Third, timing helped: the S&P 500 health care sector had hit a record high on Thursday, and investors were rotating into health care even as the broader market fell on Friday, with the Dow down about 1.24% on the day.

BioCentury noted the debut is already being read as a signal for the wider biotech IPO window, reporting that after Lycia's aftermarket surge, more biotechs are looking to Nasdaq, with companies including Rezera, TriGemX and Prana preparing public-market moves by different routes.

Key Facts

IPO price: $18.00 per share, the top of the $16–$18 range
Shares sold: 17.64 million, upsized from 14.7 million planned
Gross proceeds: approximately $317.5 million, before underwriting discounts and expenses
Valuation at pricing: about $990.6 million post-money
First-day trading: opened at $28.55, traded as high as $36.49, closed up about 67% from the IPO price, lifting its valuation to nearly $1.7 billion
Listing: Nasdaq Global Select Market, ticker LYCA; offering expected to close October 26
Use of proceeds: funding clinical trials, per the prospectus

What's Next

The immediate questions are mechanical and clinical. Mechanically, watch whether underwriters exercise their option for up to 2.646 million extra shares, and how the stock holds its first-day gains once the debut-day momentum fades — first-day pops of this size often retrace in part, and nothing about Friday's trading changes the fact that Lycia is a clinical-stage company whose value depends on trial results that are still ahead of it. Clinically, the programs to watch are LCA-0061 in allergic disease and LCA-0321 in Graves' disease, which the new capital is meant to advance. For the broader market, the real test is whether other biotechs follow Lycia through the IPO window in the coming weeks.

This post reports market news only and is not financial advice. It does not recommend buying, selling or holding any security.

Sources

FAQ

How much did Lycia Therapeutics stock rise on its first day?

Lycia (LYCA) closed Friday, October 23, 2026 up about 67% from its $18 IPO price, after opening at $28.55 and trading as high as $36.49 intraday, according to BioCentury.

How much money did Lycia raise in its IPO?

Lycia raised approximately $317.5 million in gross proceeds by selling 17.64 million shares at $18 each, in an offering upsized from the 14.7 million shares originally planned.

What does Lycia Therapeutics do?

Lycia is a clinical-stage biotech developing drugs that degrade disease-causing extracellular proteins, initially targeting autoimmune, inflammatory and allergic diseases, with lead candidates for food allergy and Graves' disease.

When does the Lycia IPO offering close?

The offering is expected to close on October 26, 2026, subject to customary closing conditions, and underwriters have a 30-day option to purchase up to 2,646,000 additional shares.